ArQule Presents Additional Clinical Biomarker Data From Phase 2 Study of Tivantinib in Hepatocellular Carcinoma at International Liver Cancer Association Conference
September 08, 2015 07:30 ET
|
ArQule, Inc.
BURLINGTON, Mass., Sept. 08, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced that additional analyses of plasma biomarkers support the prognostic and predictive role of MET...
ArQule Reports Second Quarter 2015 Financial Results
August 05, 2015 07:00 ET
|
ArQule, Inc.
BURLINGTON, Mass., Aug. 05, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced its financial results for the second quarter of 2015. For the quarter ended June 30, 2015,...